ReviewJournal of the Royal Society, Interface2025
Advantages of using complement components in preventive and therapeutic vaccine strategies for infectious and non-infectious diseases.
Review in Journal of the Royal Society, Interface, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune Camouflage inClinical ophthalmology (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complement system, a vital component of innate immunity, is indispensable to our immune defence mechanisms against microbial infections. Acting as a surveillance mechanism, it identifies and eliminates pathogens by activating several complement components and associated signalling pathways, which are also implicated in various diseases and disorders. Beyond its defensive role, the complement system has emerged as a promising target for vaccine development in therapeutic and preventive regimens, offering new vaccine strategies to combat non-infectious and infectious diseases. Activation of the complement pathways by various natural and synthetic adjuvants enhances protective immune responses, highlighting its utility in vaccine design. This approach could be useful for targeting autoimmune diseases, infectious diseases, cancer and neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.